The ultimate goal of precision medicine is a unique drug for each patient. However, this N-of-1 model directly conflicts with the current economic and regulatory system, which incentivizes developing drugs for large populations to recoup massive R&D and approval costs.

Unlike bladder cancer, prostate cancer has highly effective androgen-pathway inhibitors (ARPIs) that extend survival. This success has pushed chemotherapy and, by extension, ADC development to later treatment lines as clinicians prioritize other novel mechanisms of action first.

The standard approach to reducing cancer drug toxicity is narrowing the target to specific mutations (e.g., HER2, KRAS). While this improves safety, it drastically shrinks the addressable patient population for each new therapy. This puts immense pressure on the pharmaceutical business model, where development costs average $2.5 billion per drug.

The widely used and effective off-label combination of gemcitabine/docetaxel is rarely administered in community settings. The inexpensive drugs and long patient chair time make it a financial loss for these practices, creating an economic, not clinical, barrier to a viable treatment.

The 'safety first' mandate in drug development is flexible. For cancers like leukemia with high cure rates, highly aggressive therapies with severe side effects are deemed acceptable. The risk-benefit calculation shifts dramatically when a cure, not just management, is the goal.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

In the refractory setting for testis cancer, there is no established standard of care. This makes conducting large, randomized trials ethically and practically difficult. Therefore, well-conducted single-arm trials showing modest but meaningful activity, such as with cabozantinib, can still provide reasonable options for patients with no alternatives.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.